AffiliationTargeted Therapy Group, Institute of Cancer Sciences, University of Manchester
MetadataShow full item record
AbstractAfter years of limited success, progress of anti-cancer immuno-therapeutics has been considerable over the past decade. Key to this progress has been the application of new biological insights around the importance and nature of immune checkpoints that are able to reverse down-regulation of anti-tumor immunity. Areas covered: An overview of the preclinical and recent clinical trial data on key immuno-regulatory agents currently in development, including antibody targeting of cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death receptor 1 (PD-1) on T-lymphocytes and its principal ligand (PD-L1) on tumor cells as well as immune agonists (e.g., anti-CD40). Expert opinion: Durable long-term responses in some patients with advanced melanoma, initially with ipilimumab (anti-CTLA-4) and more recently antibodies targeting either PD-1 or PD-L1 in patients with melanoma and renal cancer, non-small-cell lung, bladder and head and neck cancers with less toxicity, have provided real optimism that immunotherapeutic approaches can improve outcomes in a wide range of cancer. The manageable tolerability of PD-1-pathway blockers and their unique mechanism of action are encouraging combination approaches. Current efforts focus on registration trials of single agents plus combinations in many different tumor types and treatment settings and identifying and developing predictive biomarkers of immunological response.
CitationImmuno-regulatory antibodies for the treatment of cancer. 2015:1-15 Expert Opin Biol Ther
JournalExpert Opinion on Biological Therapy
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
- Authors: Philips GK, Atkins M
- Issue date: 2015 Jan
- A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
- Authors: Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F
- Issue date: 2015 Aug
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
- Authors: Mahoney KM, Freeman GJ, McDermott DF
- Issue date: 2015 Apr 1
- [Cancer immunotherapy by immuno-checkpoint blockade].
- Authors: Kawakami Y
- Issue date: 2015 Oct
- Second- and third-generation drugs for immuno-oncology treatment-The more the better?
- Authors: Dempke WCM, Fenchel K, Uciechowski P, Dale SP
- Issue date: 2017 Mar